Bryan-Marrugo Owen Lloyd, Arellanos-Soto Daniel, Rojas-Martinez Augusto, Barrera-Saldaña Hugo, Ramos-Jimenez Javier, Vidaltamayo Roman, Rivas-Estilla Ana María
Department of Biochemistry and Molecular Medicine, School of Medicine, Autonomous University of Nuevo León, Monterrey, Nuevo León 64460, México.
Infectious Disease Service, School of Medicine, Autonomous University of Nuevo León, Monterrey, Nuevo León 64460, México.
Mol Med Rep. 2016 Sep;14(3):2155-63. doi: 10.3892/mmr.2016.5519. Epub 2016 Jul 13.
Dengue virus (DENV) susceptibility to cholesterol depleting treatments has been previously reported. There are numerous questions regarding how DENV seizes cellular machinery and cholesterol to improve viral production and the effect of cholesterol sequestering agents on the cellular antiviral response. The aim of the present study was to evaluate the mechanisms involved in the negative regulation of DENV replication induced by agents that diminish intracellular cholesterol levels. Cholesterol synthesis was pharmacologically (fluvastatin, atorvastatin, lovastatin, pravastatin and simvastatin treatment) and genetically (HMGCR‑RNAi) inhibited, in uninfected and DENV2‑infected hepatoma Huh‑7 cells. The cholesterol levels, DENV titer and cellular antiviral expression profile were evaluated. A reduction in the DENV titer, measured as plaque forming units, was observed in DENV‑infected cells following 48 h treatment with 10 µM fluvastatin, 10 µM atorvastatin, 20 µM lovastatin and 20 µM simvastatin, which achieved 70, 70, 65 and 55% DENV2 inhibition, respectively, compared with the untreated cells. In addition, the cytopathic effect was reduced in the statin‑treated DENV‑infected cells. Statins simultaneously reduced cholesterol levels at 48 h, with the exception of DENV2 infected cells. Genetic inhibition of cholesterol synthesis was performed using RNA interference for 3‑hydroxy‑3‑methylglutaryl‑CoA reductase (HMGCR‑siRNA), which indicated a slight reduction in DENV2 titer at 48 h post‑infection, however, with no significant reduction in cholesterol levels. In addition, DENV2 infection was observed to augment the intracellular cholesterol levels in all experimental conditions. Comparison between the cellular antiviral response triggered by DENV2 infection, statin treatment and HMGCR‑siRNA in infected, uninfected, treated and untreated Huh7 cells, showed different expression profiles for the antiviral genes evaluated. All downregulating cholesterol agents evaluated reduced the expression of genes associated with cellular immune and pro‑inflammatory responses. These results indicate that statin-mediated downregulation of DENV2 infectious particles number is independent of cholesterol levels and it is partially mediated by the modulation of the cellular antiviral profile.
登革病毒(DENV)对胆固醇消耗治疗的敏感性此前已有报道。关于DENV如何利用细胞机制和胆固醇来提高病毒产量以及胆固醇螯合剂对细胞抗病毒反应的影响,存在许多问题。本研究的目的是评估降低细胞内胆固醇水平的药物对DENV复制负调控的相关机制。在未感染和DENV2感染的肝癌Huh-7细胞中,通过药理学方法(氟伐他汀、阿托伐他汀、洛伐他汀、普伐他汀和辛伐他汀处理)和遗传学方法(HMGCR-RNAi)抑制胆固醇合成。评估胆固醇水平、DENV滴度和细胞抗病毒表达谱。在用10μM氟伐他汀、10μM阿托伐他汀、20μM洛伐他汀和20μM辛伐他汀处理48小时后,在DENV感染的细胞中观察到以空斑形成单位衡量的DENV滴度降低,与未处理的细胞相比,分别实现了70%、70%、65%和55%的DENV2抑制。此外,在他汀类药物处理的DENV感染细胞中,细胞病变效应降低。除了DENV2感染的细胞外,他汀类药物在48小时时同时降低了胆固醇水平。使用针对3-羟基-3-甲基戊二酰辅酶A还原酶(HMGCR-siRNA)的RNA干扰进行胆固醇合成的基因抑制,这表明感染后48小时DENV2滴度略有降低,然而,胆固醇水平没有显著降低。此外,在所有实验条件下均观察到DENV2感染会增加细胞内胆固醇水平。在感染、未感染、处理和未处理的Huh7细胞中,比较DENV2感染、他汀类药物处理和HMGCR-siRNA引发的细胞抗病毒反应,结果显示所评估的抗病毒基因具有不同的表达谱。所有评估的下调胆固醇药物均降低了与细胞免疫和促炎反应相关基因的表达。这些结果表明,他汀类药物介导的DENV2感染性颗粒数量的下调与胆固醇水平无关,并且部分是由细胞抗病毒谱的调节介导的。